Psychedelic drug developer Compass Pathways is preparing to talk to the FDA about filing its psilocybin therapy COMP360 for approval in treatment-resistant depression (TRD), after reporting positive ...

The Consumer Policy Center estimated that Compass’ market share was up to 40 percent after its deal for Anywhere Real Estate.

Space Compass and SWISSto12 have executed a procurement contract for the first GEO optical data relay satellite. This agreement represents a milestone toward the realisation of Space Compass’s optical ...

Investing.com - Stifel reiterated a Buy rating and $12.00 price target on Compass Therapeutics (NASDAQ:CMPX) shares, well above the current stock price of $5.10. The biotech company has delivered a ...